Biofourmis valuation, funding and investors

Biofourmis works in connected healthcare platform development, based in Boston, United States. Founded in 2015, it has about 107 employees.

Tech Companies Boston Series D

VALUATION · TODAY

$229M −16% after Series D

Range $139M – $623M · Grade C

TODAY

+12 MO

$500M

$1.00B

$1.50B

$2.00B

$2.50B

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series B $35.0M

Series C $100M

Series D $300M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY107 employees

−15%6m growth

−36%1y growth

−75%2y growth

250

500

750

Data from Jan 2021

TODAY

Predicted in 1 yr $192M −16% vs today

Predicted next raise $186M if a round comes

Winding-down probability 97%

Last round: Series D · $300M · Apr 2022
Valuation at last round: $1.30B
Headcount: 107 · shrinking
Grade: C
Founded: 2015

How VCMC values companies →

Biofourmis valuation today

VCMC values Biofourmis at $229M today, with a range of $139M to $623M and a grade of C. The valuation starts from its last funding round, a Series D round in Apr 2022.

Valuation by date (146 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Biofourmis: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2015	$5.17M	$1.88M – $14.2M	$5.41M (+5%)	before first round	–	unknown	D	0%
1 Feb 2015	$5.19M	$1.89M – $14.2M	$5.44M (+5%)	before first round	–	unknown	D	0%
1 Mar 2015	$5.21M	$1.90M – $14.3M	$5.46M (+5%)	before first round	–	unknown	D	0%
1 Apr 2015	$5.23M	$1.90M – $14.4M	$5.48M (+5%)	before first round	–	unknown	D	0%
1 May 2015	$5.25M	$1.91M – $14.4M	$5.50M (+5%)	before first round	–	unknown	D	0%
1 Jun 2015	$5.27M	$1.92M – $14.5M	$5.52M (+5%)	before first round	–	unknown	D	0%
1 Jul 2015	$5.29M	$1.93M – $14.5M	$5.54M (+5%)	before first round	–	unknown	D	0%
1 Aug 2015	$5.31M	$1.93M – $14.6M	$5.69M (+7%)	before first round	–	unknown	D	0%
1 Sep 2015	$5.33M	$1.94M – $14.6M	$5.84M (+10%)	before first round	–	unknown	D	0%
1 Oct 2015	$5.35M	$1.95M – $14.7M	$5.99M (+12%)	before first round	–	unknown	D	0%
1 Nov 2015	$5.37M	$1.96M – $14.8M	$6.16M (+15%)	before first round	–	unknown	D	0%
1 Dec 2015	$5.39M	$1.96M – $14.8M	$6.32M (+17%)	before first round	–	unknown	D	0%
1 Jan 2016	$5.41M	$1.97M – $14.9M	$6.49M (+20%)	before first round	–	unknown	D	0%
1 Feb 2016	$5.44M	$1.98M – $14.9M	$6.67M (+23%)	before first round	–	unknown	D	0%
1 Mar 2016	$5.46M	$1.99M – $15.0M	$6.84M (+25%)	before first round	–	unknown	D	0%
1 Apr 2016	$5.48M	$1.99M – $15.0M	$7.02M (+28%)	before first round	–	unknown	D	0%
1 May 2016	$5.50M	$2.00M – $15.1M	$7.21M (+31%)	before first round	–	unknown	D	0%
1 Jun 2016	$5.52M	$2.01M – $15.2M	$7.40M (+34%)	before first round	–	unknown	D	0%
1 Jul 2016	$5.54M	$2.02M – $15.2M	$7.60M (+37%)	before first round	–	unknown	D	0%
1 Aug 2016	$5.69M	$2.07M – $15.6M	$7.80M (+37%)	before first round	–	unknown	D	0%
1 Sep 2016	$5.84M	$2.13M – $16.1M	$8.01M (+37%)	before first round	–	unknown	D	0%
1 Oct 2016	$6.00M	$2.18M – $16.5M	$8.22M (+37%)	before first round	–	unknown	D	0%
1 Nov 2016	$6.16M	$2.24M – $16.9M	$8.45M (+37%)	before first round	–	unknown	D	0%
1 Dec 2016	$6.32M	$2.30M – $17.4M	$8.67M (+37%)	before first round	–	unknown	D	0%
1 Jan 2017	$6.49M	$2.36M – $17.8M	$8.90M (+37%)	before first round	–	unknown	D	0%
1 Feb 2017	$6.67M	$2.43M – $18.3M	$9.14M (+37%)	before first round	–	unknown	D	0%
1 Mar 2017	$6.83M	$2.49M – $18.8M	$9.36M (+37%)	before first round	–	unknown	D	0%
1 Apr 2017	$7.01M	$2.55M – $19.3M	$9.62M (+37%)	before first round	–	unknown	D	0%
1 May 2017	$7.20M	$2.62M – $19.8M	$9.87M (+37%)	before first round	–	unknown	D	0%
1 Jun 2017	$7.39M	$2.69M – $20.3M	$10.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2017	$7.59M	$2.76M – $20.8M	$10.4M (+37%)	before first round	–	unknown	D	0%
1 Aug 2017	$7.79M	$2.84M – $21.4M	$10.7M (+37%)	before first round	–	unknown	D	0%
1 Sep 2017	$8.01M	$2.91M – $22.0M	$11.0M (+37%)	before first round	–	unknown	D	0%
1 Oct 2017	$8.22M	$2.99M – $22.6M	$11.3M (+37%)	before first round	–	unknown	D	0%
1 Nov 2017	$8.44M	$3.07M – $23.2M	$11.6M (+37%)	before first round	–	unknown	D	0%
1 Dec 2017	$8.66M	$3.15M – $23.8M	$11.9M (+37%)	before first round	–	unknown	D	0%
1 Jan 2018	$8.90M	$3.24M – $24.4M	$12.2M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.14M	$3.33M – $25.1M	$12.5M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.36M	$3.41M – $25.7M	$12.8M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.62M	$3.50M – $26.4M	$13.2M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$9.87M	$3.59M – $27.1M	$13.5M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.1M	$3.69M – $27.8M	$13.9M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.4M	$3.79M – $28.6M	$14.3M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.7M	$3.89M – $29.4M	$14.4M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$11.0M	$4.00M – $30.2M	$14.5M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.3M	$4.10M – $30.9M	$14.7M (+30%)	before first round	–	unknown	D	0%
1 Nov 2018	$11.6M	$4.21M – $31.8M	$14.8M (+28%)	before first round	–	unknown	D	0%
1 Dec 2018	$11.9M	$4.32M – $32.6M	$14.9M (+26%)	before first round	–	unknown	D	0%
1 Jan 2019	$12.2M	$4.44M – $33.5M	$15.1M (+24%)	before first round	–	unknown	D	0%
1 Feb 2019	$12.5M	$4.56M – $34.4M	$15.2M (+21%)	before first round	–	unknown	D	0%
1 Mar 2019	$12.8M	$4.67M – $35.3M	$15.3M (+19%)	before first round	–	unknown	D	0%
1 Apr 2019	$13.2M	$4.80M – $36.2M	$15.5M (+17%)	before first round	–	unknown	D	0%
1 May 2019	$13.5M	$4.93M – $37.2M	$15.6M (+15%)	before first round	–	unknown	D	0%
22 May 2019	$250M	$164M – $571M	$375M (+50%)	after a round	–	unknown	C	0%
1 Jun 2019	$253M	$164M – $571M	$375M (+48%)	after a round	–	unknown	C	0%
1 Jul 2019	$262M	$164M – $571M	$375M (+43%)	after a round	–	unknown	C	0%
1 Aug 2019	$271M	$164M – $571M	$375M (+38%)	after a round	–	unknown	C	0%
1 Sep 2019	$280M	$164M – $571M	$375M (+34%)	after a round	–	unknown	C	0%
1 Oct 2019	$290M	$164M – $571M	$375M (+29%)	after a round	–	unknown	C	0%
1 Nov 2019	$300M	$164M – $571M	$375M (+25%)	after a round	–	unknown	C	0%
1 Dec 2019	$310M	$164M – $571M	$375M (+21%)	after a round	–	unknown	C	0%
1 Jan 2020	$321M	$164M – $571M	$375M (+17%)	after a round	–	unknown	C	0%
1 Feb 2020	$332M	$164M – $571M	$375M (+13%)	after a round	–	unknown	C	0%
1 Mar 2020	$343M	$164M – $571M	$375M (+9%)	after a round	–	unknown	C	0%
1 Apr 2020	$355M	$164M – $571M	$375M (+6%)	after a round	–	unknown	C	0%
1 May 2020	$367M	$164M – $571M	$375M (+2%)	after a round	–	unknown	C	0%
1 Jun 2020	$375M	$162M – $571M	$375M (0%)	after a round	–	unknown	C	0%
1 Jul 2020	$375M	$155M – $571M	$375M (0%)	after a round	–	unknown	C	0%
1 Aug 2020	$375M	$148M – $571M	$375M (0%)	after a round	–	unknown	C	0%
1 Sep 2020	$375M	$142M – $571M	$375M (0%)	after a round	–	unknown	C	0%
4 Sep 2020	$707M	$498M – $1.3B	$918M (+30%)	after a round	–	unknown	B	0%
1 Oct 2020	$721M	$498M – $1.3B	$918M (+27%)	after a round	–	unknown	B	0%
1 Nov 2020	$737M	$498M – $1.3B	$918M (+25%)	after a round	–	unknown	B	0%
1 Dec 2020	$753M	$498M – $1.3B	$918M (+22%)	after a round	–	unknown	B	0%
1 Jan 2021	$770M	$498M – $1.3B	$918M (+19%)	after a round	140	unknown	B	0%
1 Feb 2021	$787M	$498M – $1.3B	$918M (+17%)	after a round	140	unknown	B	0%
1 Mar 2021	$803M	$498M – $1.3B	$918M (+14%)	after a round	140	unknown	B	0%
1 Apr 2021	$821M	$498M – $1.3B	$918M (+12%)	after a round	140	flat	B	0%
1 May 2021	$902M	$555M – $1.5B	$1.0B (+14%)	after a round	230	growing	B	0%
1 Jun 2021	$930M	$555M – $1.5B	$1.0B (+10%)	after a round	230	growing	B	0%
1 Jul 2021	$959M	$555M – $1.5B	$1.0B (+7%)	after a round	230	growing	B	0%
1 Aug 2021	$990M	$555M – $1.5B	$1.0B (+3%)	after a round	230	growing	B	0%
1 Sep 2021	$1.0B	$555M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Oct 2021	$1.0B	$558M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Nov 2021	$1.0B	$561M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Dec 2021	$1.0B	$564M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Jan 2022	$1.0B	$567M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Feb 2022	$1.0B	$571M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Mar 2022	$1.0B	$573M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
1 Apr 2022	$1.0B	$577M – $1.5B	$1.0B (0%)	after a round	230	growing	B	0%
27 Apr 2022	$1.3B	$1.1B – $1.9B	$1.7B (+30%)	after a round	230	growing	A	0%
1 May 2022	$1.3B	$1.1B – $1.9B	$1.7B (+30%)	after a round	230	growing	A	0%
1 Jun 2022	$1.3B	$1.1B – $1.9B	$1.7B (+27%)	after a round	230	growing	A	0%
1 Jul 2022	$1.4B	$1.1B – $1.9B	$1.7B (+24%)	after a round	230	growing	A	0%
1 Aug 2022	$1.4B	$1.1B – $1.9B	$1.7B (+21%)	after a round	230	growing	A	0%
1 Sep 2022	$1.4B	$1.1B – $1.9B	$1.7B (+19%)	after a round	230	growing	A	0%
1 Oct 2022	$1.5B	$1.1B – $1.9B	$1.7B (+16%)	after a round	230	growing	A	0%
1 Nov 2022	$1.5B	$1.1B – $1.9B	$1.7B (+13%)	after a round	230	unknown	A	0%
1 Dec 2022	$1.5B	$1.1B – $1.9B	$1.7B (+11%)	after a round	230	unknown	A	0%
1 Jan 2023	$1.6B	$1.1B – $1.9B	$1.7B (+9%)	after a round	580	unknown	A	0%
1 Feb 2023	$1.6B	$1.1B – $1.9B	$1.7B (+6%)	after a round	580	unknown	A	0%
1 Mar 2023	$1.6B	$1.1B – $1.9B	$1.7B (+4%)	after a round	580	unknown	A	0%
1 Apr 2023	$1.7B	$1.1B – $1.9B	$1.7B (+2%)	after a round	580	unknown	A	0%
1 May 2023	$1.7B	$1.1B – $1.9B	$1.7B (0%)	after a round	580	unknown	A	0%
1 Jun 2023	$1.7B	$1.1B – $1.9B	$1.7B (0%)	after a round	580	unknown	A	0%
1 Jul 2023	$1.7B	$1.0B – $1.9B	$1.7B (0%)	after a round	580	unknown	B	0%
1 Aug 2023	$1.7B	$978M – $1.9B	$1.7B (0%)	after a round	580	unknown	B	0%
1 Sep 2023	$1.7B	$933M – $1.9B	$1.7B (0%)	after a round	580	unknown	B	0%
1 Oct 2023	$1.5B	$885M – $1.8B	$1.3B (-11%)	after a round	540	flat	B	36%
1 Nov 2023	$1.5B	$844M – $1.8B	$1.3B (-11%)	after a round	540	flat	B	36%
1 Dec 2023	$1.5B	$805M – $1.8B	$1.3B (-11%)	after a round	540	flat	B	36%
1 Jan 2024	$1.4B	$768M – $1.8B	$1.3B (-11%)	after a round	540	flat	B	36%
1 Feb 2024	$1.1B	$713M – $1.7B	$785M (-27%)	after a round	460	down	B	97%
1 Mar 2024	$1.1B	$679M – $1.7B	$767M (-27%)	after a round	450	down	B	97%
1 Apr 2024	$1.0B	$646M – $1.7B	$748M (-28%)	after a round	450	down	B	97%
1 May 2024	$976M	$615M – $1.7B	$657M (-33%)	after a round	450	down	B	97%
1 Jun 2024	$953M	$584M – $1.7B	$636M (-33%)	after a round	450	down	B	97%
1 Jul 2024	$930M	$556M – $1.8B	$616M (-34%)	after a round	450	down	B	97%
1 Aug 2024	$908M	$528M – $1.8B	$596M (-34%)	after a round	420	down	C	97%
1 Sep 2024	$886M	$502M – $1.8B	$577M (-35%)	after a round	420	down	C	97%
1 Oct 2024	$865M	$478M – $1.8B	$559M (-35%)	after a round	420	down	C	97%
1 Nov 2024	$669M	$454M – $1.4B	$392M (-41%)	after a round	390	shrinking	B	97%
1 Dec 2024	$645M	$432M – $1.3B	$376M (-42%)	after a round	390	shrinking	B	97%
1 Jan 2025	$621M	$411M – $1.3B	$361M (-42%)	after a round	390	shrinking	B	97%
1 Feb 2025	$598M	$391M – $1.3B	$346M (-42%)	after a round	390	shrinking	C	97%
1 Mar 2025	$578M	$373M – $1.3B	$333M (-42%)	after a round	390	shrinking	C	97%
1 Apr 2025	$557M	$355M – $1.3B	$319M (-43%)	after a round	390	shrinking	C	97%
1 May 2025	$709M	$337M – $1.9B	$459M (-35%)	after a round	390	down	C	89%
1 Jun 2025	$738M	$321M – $1.9B	$490M (-34%)	after a round	390	down	C	82%
1 Jul 2025	$464M	$305M – $1.0B	$269M (-42%)	after a round	177	shrinking	C	97%
1 Aug 2025	$444M	$290M – $1.0B	$258M (-42%)	after a round	166	shrinking	C	97%
1 Sep 2025	$426M	$276M – $983M	$247M (-42%)	after a round	166	shrinking	C	97%
1 Oct 2025	$409M	$262M – $963M	$237M (-42%)	after a round	166	shrinking	C	97%
1 Nov 2025	$392M	$249M – $943M	$227M (-42%)	after a round	150	shrinking	C	97%
1 Dec 2025	$376M	$237M – $924M	$217M (-42%)	after a round	150	shrinking	C	97%
1 Jan 2026	$361M	$226M – $905M	$208M (-42%)	after a round	150	shrinking	C	97%
1 Feb 2026	$346M	$214M – $886M	$199M (-42%)	after a round	126	shrinking	C	97%
1 Mar 2026	$333M	$205M – $869M	$193M (-42%)	after a round	126	shrinking	C	97%
1 Apr 2026	$319M	$195M – $851M	$193M (-40%)	after a round	126	shrinking	C	97%
1 May 2026	$293M	$185M – $717M	$193M (-34%)	after a round	112	shrinking	C	97%
1 Jun 2026	$281M	$176M – $700M	$193M (-31%)	after a round	112	shrinking	C	97%
1 Jul 2026	$269M	$168M – $683M	$192M (-29%)	after a round	112	shrinking	C	97%
1 Aug 2026	$258M	$159M – $666M	$192M (-25%)	after a round	109	shrinking	C	97%
1 Sep 2026	$247M	$151M – $650M	$192M (-22%)	after a round	109	shrinking	C	97%
1 Oct 2026	$237M	$144M – $635M	$192M (-19%)	after a round	107	shrinking	C	97%
24 Oct 2026	$229M	$139M – $623M	$192M (-16%)	after a round	107	shrinking	C	97%

Key facts about Biofourmis

Founded: 2015
Headquarters: Boston, United States
Employees: about 107 -36% in a year
Total raised: $435M
Funding rounds: 3
Last round: Series D Apr 2022

Biofourmis was founded in 2015 by Kuldeep Singh Rajput.

Biofourmis funding history

Biofourmis has 3 funding rounds on record, from May 2019 to Apr 2022, $435M in total. The latest disclosed valuation is $1.30B post-money (Series D, Apr 2022).

Series D 26 Apr 2022
Led by General Atlantic; with CVS Health, SoftBank Vision Fund, Openspace Capital, MassMutual Ventures, Sequoia Capital, EDBI.
Sources: alleywatch.com, biofourmis.com, mobihealthnews.com and 1 more
$300M
$1.30B post-money
Series C 3 Sep 2020
Led by SoftBank Vision Fund; with Openspace Ventures, MassMutual Ventures, Sequoia Capital, EDBI.
Sources: prnewswire.com, biofourmis.com, mobihealthnews.com and 1 more
$100M
Series B 21 May 2019
Led by Sequoia India, MassMutual Ventures; with EDBI, Jianke, Openspace Ventures, Aviva Ventures, SGInnovate.
Sources: finsmes.com, techcrunch.com, biofourmis.com and 2 more
$35M

Biofourmis investors

12 investors have backed Biofourmis; MassMutual Ventures, SoftBank Vision Fund and General Atlantic and 1 more led at least one round.

SoftBank Vision Fund lead, 2 rounds
General Atlantic lead
Sequoia India lead
EDBI 3 rounds
Openspace Ventures 2 rounds
Sequoia Capital 2 rounds
Aviva Ventures
CVS Health
Jianke
SGInnovate

What Biofourmis does

Biofourmis works in tech companies, with 15 recorded offerings and customers in healthcare.

Biofourmis is a healthcare technology company engaged in developing connected technology platforms that integrate biosensor data, FDA-cleared algorithms, and analytics to support personalized interventions in drug life cycle management, care delivery, and clinical trials. The company serves global health systems, hospitals, and payers, providing solutions such as hospital at home, timely discharge, SNF at home, and remote patient management. Biofourmis also offers care coordination, nursing, diagnostics, and medication optimization services, supported by a network of clinicians and service partners. The company is committed to AI-driven solutions and data science to improve patient outcomes and operational efficiency.

Description from Veridion's company data.

Products and services

Connected Healthcare Platform Development
Biosensor Data Integration and Analytics
AI-Driven Clinical Decision Support
Personalized Patient Intervention Delivery
Hospital at Home Services
SNF at Home Services
Remote Patient Monitoring Services
Timely Patient Discharge Services
Care Coordination Services
Nursing Support Services
Clinical Diagnostics Services
Medication Optimization Services
Drug Life Cycle Management Solutions
Clinical Trial Management Solutions
Data-Driven Patient Outcome Improvement Services

Markets

Healthcare

Technology

Biosensor Data Integration
AI-Driven In-Home Care
Advanced Analytics for Personalized Interventions

Certifications

FDA cleared

Business model

Business-to-Business
Service Provider
Healthcare
Enterprise

Industry codes (NAICS)

541512 Computer Systems Design Services 50% match
621999 All Other Miscellaneous Ambulatory Health Care Services 50% match

Questions about Biofourmis

What is Biofourmis worth?

Valuation $229M (range $139M to $623M), as of 24 Oct 2026. The last disclosed valuation was $1.30B (Series D, Apr 2022).

Has Biofourmis raised money?

Biofourmis has 3 funding rounds on record, from May 2019 to Apr 2022, $435M in total. The latest disclosed valuation is $1.30B post-money (Series D, Apr 2022).

Who has invested in Biofourmis?

MassMutual Ventures, SoftBank Vision Fund, General Atlantic, Sequoia India, EDBI and Openspace Ventures, and 6 more. Lead investors include MassMutual Ventures, SoftBank Vision Fund, General Atlantic and Sequoia India.

How many people work at Biofourmis?

About 107, down 36% over the last year. Headcount rose from 140 in Jan 2021 to 580 in Jan 2023, then fell to 107 in Sep 2026.

What does Biofourmis do?

Biofourmis works in tech companies, with 15 recorded offerings and customers in healthcare. Its main offerings are connected healthcare platform development, biosensor data integration and analytics and AI-Driven clinical decision support.

When was Biofourmis founded, and where is it based?

Biofourmis was founded in 2015 and is based in Boston, United States. It has about 107 employees, down 36% over the last year.

How we value companies Report an issue